Neutropenic Fever Management

Initial Assessment and Treatment

The American College of Physicians recommends initiating empirical broad-spectrum antipseudomonal beta-lactam antibiotics within 1 hour of fever onset, as each hour of delay decreases survival by 7.6% 1, 2
Obtain blood cultures from peripheral sites and central venous catheters (if present) before antibiotics, but never delay antibiotic administration for culture results 1, 2
Blood cultures detect bacteremia in only 30% of febrile neutropenia cases, so negative cultures should never alter initial empirical therapy 1, 2

Choose ONE of the following antipseudomonal beta-lactam monotherapies, such as meropenem, imipenem/cilastatin, piperacillin-tazobactam, or ceftazidime, considering local antibiogram data and recent antibiotic exposure 1, 2
The Infectious Diseases Society of America recommends carbapenems (meropenem/imipenem) for superior coverage of ESBL-producing organisms common in cancer patients 1

Add empirical antifungal therapy if fever persists beyond 96-120 hours (4-5 days) despite appropriate antibiotics, using liposomal amphotericin B or echinocandin (caspofungin or micafungin) as first-line choices 6, 2
For patients with lung infiltrates, use voriconazole or liposomal amphotericin B (mold-active therapy) 5, 3, 7

Target mean arterial pressure ≥65 mmHg, central venous pressure 8-12 mmHg, urine output ≥0.5 mL/kg/hour, and central venous oxygen saturation ≥70% with aggressive fluid resuscitation 1, 2
Use crystalloids preferentially over colloids for fluid management 2

De-escalate to narrower spectrum antibiotics when the patient is afebrile for 72 hours, has no clinical evidence of ongoing infection, and culture results show specific pathogen susceptibility 1, 2
Extend antibiotic therapy beyond 10 days if there is a slow clinical response, documented fungal infection, persistent profound neutropenia, or inadequate source control 1, 2

Never delay antibiotics for culture results, as mortality increases 7.6% per hour of delay 1, 2
Avoid routine aminoglycoside combinations in standard febrile neutropenia due to nephrotoxicity without benefit 1, 2
Do not use vancomycin empirically unless specific risk factors are present, to minimize the development of resistance 4